Anheuser-Busch Won’t Fund Controversial NIH Alcohol Study

The company’s announcement comes weeks after enrollment was suspended.

Written byShawna Williams
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

Large building with ISTOCK, DEBRAMILLETUpdate (June 18): STAT News reports that NIH has shut down the alcohol study. Lawrence Tabak, the head of a task force charged with examining the study, says, “the nature of the engagement with industry representatives calls into question the impartiality of the process.”

Anheuser-Busch InBev has withdrawn a $15-million funding commitment for a mammoth National Institutes of Health study on the effects of moderate alcohol consumption, The New York Times reports. The company’s announcement, made on Friday (June 8), comes after the planned study drew scrutiny over potential conflicts of interest on the part of NIH, which had courted corporate sponsors with the prospect of producing evidence of health benefits of regular drinking.

The planned $100-million study, administered by the NIH’s National Institute of Alcohol Abuse and Alcoholism (NIAAA) would assign thousands of participants either to have an alcoholic drink every day or abstain, and track their health outcomes and mortality over six years. The New York Times reported in March that in an effort to get beverage ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • Shawna was an editor at The Scientist from 2017 through 2022. She holds a bachelor’s degree in biochemistry from Colorado College and a graduate certificate in science communication from the University of California, Santa Cruz. Previously, she worked as a freelance editor and writer, and in the communications offices of several academic research institutions. As news director, Shawna assigned and edited news, opinion, and in-depth feature articles for the website on all aspects of the life sciences. She is based in central Washington State, and is a member of the Northwest Science Writers Association and the National Association of Science Writers.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies